Evercore Wealth Management LLC Purchases 4,466 Shares of Becton, Dickinson and Company $BDX

Evercore Wealth Management LLC raised its position in Becton, Dickinson and Company (NYSE:BDX) by 175.7% during the first quarter, Holdings Channel.com reports. The fund owned 7,008 shares of the medical instruments supplier’s stock after purchasing an additional 4,466 shares during the quarter. Evercore Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $1,102,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Imprint Wealth LLC bought a new stake in shares of Becton, Dickinson and Company in the third quarter worth about $25,000. Steph & Co. raised its position in Becton, Dickinson and Company by 95.6% during the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 65 shares during the last quarter. SHP Wealth Management bought a new position in Becton, Dickinson and Company during the 4th quarter valued at approximately $26,000. Meeder Asset Management Inc. lifted its holdings in Becton, Dickinson and Company by 152.2% in the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 102 shares during the period. Finally, Main Street Group LTD bought a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth approximately $29,000. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Up 4.6%

Shares of NYSE:BDX opened at $166.21 on Wednesday. The firm has a market capitalization of $45.80 billion, a P/E ratio of 42.08, a P/E/G ratio of 11.24 and a beta of 0.21. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. The stock has a 50 day moving average price of $150.67 and a 200-day moving average price of $164.15. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.13. The company had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm’s revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the company posted $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 12.62 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is 106.33%.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on BDX. Barclays boosted their target price on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. UBS Group began coverage on shares of Becton, Dickinson and Company in a report on Tuesday. They issued a “buy” rating and a $190.00 price target on the stock. Weiss Ratings lowered shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Bank of America dropped their target price on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. Finally, The Goldman Sachs Group cut their target price on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 27th. Eight research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $180.93.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the sale, the executive vice president owned 13,172 shares of the company’s stock, valued at $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer owned 110,163 shares in the company, valued at approximately $16,122,355.05. This trade represents a 2.45% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 5,189 shares of company stock worth $765,661 over the last ninety days. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.